NRXS (Neuraxis) Q2 2026: 116% Revenue Growth Driven by Insurance Coverage Expansion and Commercial Execution
Neuraxis demonstrated strong top-line momentum with a 116% year-over-year revenue increase, fueled by expanded insurance coverage and targeted commercial investments. The company is aggressively scaling in markets with payer support while advancing a new Veterans Administration channel. Execution discipline and payer engagement remain pivotal for sustaining growth and approaching profitability.
Summary
- Insurance Coverage as Growth Catalyst: Strategic payer engagement and CPT code adoption underpin scalable demand expansion.
- Commercial Execution Focus: Targeted sales force expansion and clinical advocacy drive utilization in covered markets.
- Veterans Administration Channel Initiation: Early VA orders and dedicated reps signal a promising secondary growth platform.
Business Overview
Neuraxis operates as a medical technology company specializing in IB STEM, a neuromodulation therapy targeting pediatric functional abdominal pain and related disorders. The company generates revenue primarily through device sales reimbursed by insurance payers, with major segments including commercial pediatric markets and emerging Veterans Administration (VA) healthcare channels.
Performance Analysis
In Q2 2026, Neuraxis delivered $1.928 million in revenue, more than doubling the $894,000 reported in Q2 2025, reflecting a 116% year-over-year increase. This acceleration stems from broader adoption of the Category 1 CPT code for PENFS, which has enhanced payer reimbursement and shifted sales mix away from discounted financial assistance toward higher-margin, fully reimbursed procedures. The average selling price per device rose approximately 28% year-over-year to $992, driven by this favorable payer mix shift.
Gross margin expanded by over 230 basis points to 85.9%, reflecting improved revenue quality and operational leverage. Operating expenses increased by 53% year-over-year to $3.8 million, driven by expanded selling efforts, clinical research, and administrative investments to support market access and payer engagement. Despite higher expenses, operating leverage improved as revenue growth outpaced expense increases by two to four times. The company reported an operating loss of $2.1 million, a 24% increase compared to the prior year, attributed mainly to strategic investments in commercial infrastructure and payer coverage expansion.
- Revenue Quality Improvement: Shift from discounted to fully reimbursed sales enhanced average selling price and margin potential.
- Operating Leverage Emerging: Revenue growth substantially outpaced expense increases, signaling scalable business model progress.
- Investment in Commercial and Clinical Resources: Increased headcount and R&D spend support accelerated adoption and evidence generation.
These results affirm the company’s proof of concept under the new CPT coding environment and highlight the critical role of insurance coverage in unlocking scalable growth.
Executive Commentary
"Our strategy is centered on two priorities. Number one, securing the remaining insurance coverage, which I have meaningful updates to report today. And number two, maximizing execution in covered markets while positioning the organization to scale rapidly as new coverage comes online."
Brian Carrico, Chief Executive Officer
"Our operating expenses did increase in the second quarter, and it's because of decisions we made in the second quarter from what we learned in the first quarter. We hired a few more sales personnel to drive revenue... We do expect revenue generation from hiring those people."
Tim Hendricks, Chief Financial Officer
Strategic Positioning
1. Insurance Coverage Expansion as Growth Foundation
Neuraxis views insurance policy coverage as the single most important lever for scalable growth. While the Category 1 CPT code, effective January 1, 2026, has catalyzed payer acceptance, management emphasizes that coverage from multiple large commercial payers is necessary to unlock full market potential. The company’s recent direct engagement with medical directors at two major payers, yielding positive indications, underpins confidence in additional coverage by late 2026 or early 2027. This coverage expansion aims to surpass a critical threshold of approximately 70% covered lives per hospital, a key condition for institutional commitment to aggressive programs.
2. Focused Commercial Execution in Covered Markets
Neuraxis is concentrating commercial resources on states and accounts where insurance coverage is robust. The commercial organization has been realigned under dedicated sales and marketing leadership, with new hires including digital marketing experts, medical science liaisons, and clinical adoption directors. This targeted approach addresses critical adoption drivers: payer support, physician champions, and operational clinic capacity. The company is deliberately avoiding broad expansion into markets lacking sufficient payer coverage, prioritizing depth over breadth to maximize return on investment.
3. Veterans Administration Channel Development
The VA healthcare system represents a significant secondary growth platform with nearly 7 million active patients annually. Neuraxis recently secured a federal supply schedule contract and has initiated sales efforts with 1099 territory representatives targeting VA hospitals. Early order activity from three small territories validates the opportunity. The company plans to expand VA coverage aggressively in late 2026 and into 2027, leveraging a sales model with experienced reps compensated on commission, consistent with successful med tech practices in the VA market.
4. Clinical Evidence and R&D Investment
While the primary commercial focus remains on pediatric functional abdominal pain, Neuraxis is supporting investigator-initiated randomized controlled trials (RCTs) in adult functional dyspepsia and cyclic vomiting syndrome. These studies are modest in scale, primarily covering device costs and partial research coordination, with no large-scale CRO expenditures anticipated. The clinical data generated will support future payer coverage expansion in adult markets, but current resources remain concentrated on maximizing existing indications and coverage.
5. Operational Discipline and Capital Allocation
Management maintains a disciplined approach to capital deployment, balancing aggressive commercial investments with prudent expense management. The company’s 2026 burn rate has improved significantly compared to 2025, but increased hiring and market access activities are expected to raise operating expenses in the second half of the year. Leadership emphasizes that near-term profitability is secondary to revenue growth in covered markets, anticipating that expanded payer coverage will drive a path to cash flow breakeven in the future.
Key Considerations
Neuraxis’ Q2 results highlight a critical inflection point where insurance coverage and commercial execution converge to drive growth. Investors should consider the following:
- Payer Coverage as a Bottleneck: Current penetration remains low despite policy availability; additional payer wins are essential to unlock broader adoption.
- Commercial Saturation Strategy: Focused resource allocation in states with strong coverage aims to optimize utilization before expanding geographically.
- VA Channel as Growth Diversifier: Early traction in the VA market offers a non-commercial payer pathway for expansion, reducing dependency on commercial coverage.
- Clinical Evidence Pipeline: Ongoing RCTs in adult indications support medium-term growth, but near-term emphasis remains on pediatric markets.
- Operating Expense Trajectory: Increased SG&A and R&D spending will pressure near-term profitability but are intended to accelerate revenue growth.
Risks
The primary risks include the timing and success of securing additional insurance coverage, which remains unpredictable despite positive payer engagements. Operational execution risks include the ability to effectively saturate covered markets and convert coverage into utilization. Financially, increased operating expenses may delay profitability if revenue growth does not meet expectations. Regulatory or reimbursement changes and competitive dynamics in neuromodulation therapies also pose potential headwinds.
Forward Outlook
For Q3 2026, Neuraxis expects continued revenue growth driven by expanded commercial sales efforts in covered states and initial contributions from the VA channel. Management anticipates hiring additional commercial personnel and market access experts to support this growth. For full-year 2026, guidance reflects sustained double-digit revenue growth with operating expenses increasing in the second half due to strategic investments. The company remains focused on achieving cash flow breakeven contingent on expanded payer coverage and execution success.
- Q3 2026 revenue growth supported by market saturation and VA expansion.
- Increased SG&A and R&D investments to accelerate adoption and coverage.
- Full-year 2026 operating loss expected to widen before improvement in 2027.
Takeaways
Neuraxis is navigating a pivotal growth phase where insurance coverage and focused commercial execution are unlocking demand in a specialized pediatric neuromodulation market. The company’s disciplined strategy prioritizes markets with existing payer support, while building infrastructure to scale as new coverage is secured. The VA healthcare system emerges as a promising additional growth vector, potentially mitigating reliance on commercial payers. Although operating losses are expanding due to strategic investments, improving gross margins and revenue growth trajectories suggest operational leverage is materializing. Investors should monitor payer coverage developments and commercial execution efficiency as key indicators of the company’s path to profitability.
- Coverage-Driven Growth: Payer engagement is the linchpin for scaling adoption and revenue quality.
- Execution Intensity: Commercial team expansion and clinical advocacy are critical to converting coverage into utilization.
- VA Channel Potential: Early traction in VA hospitals offers a differentiated growth avenue less dependent on commercial insurance dynamics.
Conclusion
Neuraxis’ Q2 2026 results validate the strategic importance of insurance coverage expansion and targeted commercial execution in driving robust revenue growth. The company’s deliberate focus on covered markets and the emerging VA channel position it well for scaling adoption, though near-term profitability remains challenged by necessary investments. Continued progress in payer coverage and operational execution will be essential to sustain momentum and achieve long-term financial objectives.
Industry Read-Through
Neuraxis’ experience underscores the critical role of insurance reimbursement policy in enabling adoption of innovative medical therapies. The company’s success with CPT code implementation and payer engagement provides a blueprint for other med tech firms seeking scalable commercial models in specialized treatment areas. The focus on integrating clinical evidence, payer advocacy, and operational readiness highlights the multifaceted challenges in commercializing novel therapies. The growing emphasis on alternative channels such as the VA system may signal broader industry trends toward diversified reimbursement pathways beyond traditional commercial payers.